Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot–Containing Protein
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Sclerosteosis is an autosomal recessive sclerosing bone dysplasia characterized by progressive skeletal overgrowth. The majority of affected individuals have been reported in the Afrikaner population of South Africa, where a high incidence of the disorder occurs as a result of a founder effect. Homozygosity mapping in Afrikaner families along with analysis of historical recombinants localized sclerosteosis to an interval of approximately 2 cM between the loci D17S1787 and D17S930 on chromosome 17q12-q21. Here we report two independent mutations in a novel gene, termed "SOST." Affected Afrikaners carry a nonsense mutation near the amino terminus of the encoded protein, whereas an unrelated affected person of Senegalese origin carries a splicing mutation within the single intron of the gene. The SOST gene encodes a protein that shares similarity with a class of cystine knot-containing factors including dan, cerberus, gremlin, prdc, and caronte. The specific and progressive effect on bone formation observed in individuals affected with sclerosteosis, along with the data presented in this study, together suggest that the SOST gene encodes an important new regulator of bone homeostasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutations in genes that have highly enriched expression in osteocytes cause rare bone and mineral disorders.”
From Osteocyte transcriptome mapping identifies a molecular landscape controlling skeletal homeostasis and susceptibility to skeletal disease (2021) · cites this paper as [17]
Citations
Cites
Bone: Formation by Autoinduction
Urist, M. R. (1965) · Science · doi:10.1126/science.150.3698.893 · Cited by 5,546 · cited 1×
“Although this family of morpho-gens was originally identified on the basis of bone-in-ducing activity (Urist 1965), a number of these factors have been shown to be critical for very early stages of embryogenesis and fetal development.”
Prediction of complete gene structures in human genomic DNA
Burge, C., & Karlin, S. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.0951 · Cited by 4,228 · cited 8×
“The novel variant gene (designated “P50gsc3”) predicted by GENSCAN was located between markers D17S951 and D17S1860 (fig.”
InfluentialA comprehensive genetic map of the human genome based on 5,264 microsatellites
Dib, C., Fauré, S., Fizames, C., Samson, D., Drouot, N., Vignal, A., Millasseau, P., Marc, S., Kazan, J., Seboun, E., et al. (1996) · Nature · doi:10.1038/380152a0 · Cited by 2,928 · cited 3×
“D17S1793, D17S1789, D17S951, and D17S1860 within the critical region bounded by D17S1787 and D17S930, an interval of ∼ 2 cM (Dib et al. 1996) on the cytogenetic border between the chromosomal bands 17q12–q21.”
Bone morphogenetic proteins: multifunctional regulators of vertebrate development.
Hogan, B. L. (1996) · Genes & Development · doi:10.1101/gad.10.13.1580 · Cited by 1,962
Therapeutic Approaches to Bone Diseases
Rodan, G. A., & Martin, T. J. (2000) · Science · doi:10.1126/science.289.5484.1508 · Cited by 1,767 · cited 1×
“Currently there is no effective treatment for the restoration of normal bone mass in individuals with pathologically low skeletal density, and there is a large unmet need for therapy that can increase bone deposition in osteoporosis (Rodan and Martin 2000).”
BackgroundEasy calculations of lod scores and genetic risks on small computers.
Lathrop, M. G., & Lalouel, J.-M. (1984) · Europe PMC (PubMed Central) · Cited by 1,526
Faster sequential genetic linkage computations.
Cottingham, R. W., Idury, R. M., & Schäffer, A. A. (1993) · Europe PMC (PubMed Central) · Cited by 1,364
Nonsense-mediated mRNA decayin health and disease
Frischmeyer, P. A. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.10.1893 · Cited by 992 · cited 1×
“The relatively low levels of mutant transcripts observed could be the result of nonsense-mediated mRNA decay, as the inclusion of intronic sequence introduced an in-frame nonsense codon (Frischmeyer and Dietz 1999; Hentze and Kulozik 1999).”
BackgroundHomozygosity Mapping: A Way to Map Human Recessive Traits with the DNA of Inbred Children
Lander, E. S., & Botstein, D. (1987) · Science · doi:10.1126/science.2884728 · Cited by 875
FORMATION AND FUNCTION OF SPEMANN'S ORGANIZER
Harland, R., & Gerhart, J. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.611 · Cited by 839 · cited 1×
“In addition, the requirement for the coordinated expression of negative regulators of BMP activity, such as noggin and chordin, as well as members of the dan family, has been well described (Harland and Gerhart 1997; Sasai and De Robertis 1997; Hsu et al. 1998).”
Background
Research works printed but not linked: 3
- Gardner J (1999) Profound childhood deafness in South Africa: a clinical and molecular genetic approach. Ph.D. thesis, University of Cape Town, Cape Town
- Hausen, 1967, Sklerosteose, Vol. 6, 351
- Peitruschka, 1958, Weitere Mitteilungen über die Marmorknochenkrankheit (Albers-Schonbergsche Krankheit) nebst Bemerkungen zur Differentialdiagnose, Klin Monatbl, 132, 509
Cited by
Items 201–300 of 1,000
Zankl, A., Duncan, E. L., Leo, P. J., Clark, G. R., Glazov, E. A., Addor, M., Herlin, T., Kim, C. A., Leheup, B., McGill, J., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.01.003 · Cited by 120
Bovijn, J., Krebs, K., Chen, C.-Y., Boxall, R., Censin, J. C., Ferreira, T., Pulit, S. L., Glastonbury, C. A., Laber, S., Millwood, I. Y., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay6570 · Cited by 119
“Loss-of-function mutations in SOST lead to sclerosteosis, a rare autosomal recessive condition characterized by bone overgrowth (6).”
Roles of Wnt signals in bone resorption during physiological and pathological states
Maeda, K., Takahashi, N., & Kobayashi, Y. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0974-0 · Cited by 127
“Sclerostin, a secreted cysteine-knot protein from the DAN family has been identified as causative of sclerosteosis [32, 33].”
BackgroundGregson, C. L., Hardcastle, S., Cooper, C. C., & Tobias, J. H. (2013) · Rheumatology · doi:10.1093/rheumatology/ket007 · Cited by 132
Bone morphogenetic proteins and their antagonists: current and emerging clinical uses
Ali, I., & Brazil, D. P. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12724 · Cited by 131
“Mutations in the BMP antagonists noggin and sclerostin cause brachydactyly (lack of digits; Lehmann et al., 2007), and sclerosteosis characterized by fused digits and excessive bone growth (Brunkow et al., 2001).”
BackgroundMechanisms and Regulation of Epithelial Ca2+ Absorption in Health and Disease
Suzuki, Y., Landowski, C. P., & Hediger, M. A. (2007) · Annual Review of Physiology · doi:10.1146/annurev.physiol.69.031905.161003 · Cited by 115
TNF‐α Upregulates Sclerostin Expression in Obese Mice Fed a High‐Fat Diet
Baek, K., Hwang, H. R., Park, H., Kwon, A., Qadir, A. S., Ko, S., Woo, K. M., Ryoo, H., Kim, G., & Baek, J. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24487 · Cited by 111
“J o u r n a l o fl Cellular Physiology 2 0 1 3 W I L E Y P E R I O D I C A L S , I N C . mutations and sost-deficient mice exhibit very high bone mass, suggesting that this molecule has a key role in the regulation of bone mass (Brunkow et al., 2001; Li et al., 2008).”
BackgroundCalabrese, G. M., Mesner, L. D., Stains, J. P., Tommasini, S. M., Horowitz, M. C., Rosen, C. J., & Farber, C. R. (2017) · Cell Systems · doi:10.1016/j.cels.2016.10.014 · Cited by 113
“…and sclerostin (SOST), which are among the best-known and most well-characterized genes involved in the regulation of osteoblast-lineage cells and BMD (Balemans et al., 2001; Brunkow et al., 2001; Gong et al., 2001; Little et al., 2002; Nakashima et al., 2002; Simonet et al., 1997).”
BackgroundCurrent and Future Concepts for the Treatment of Impaired Fracture Healing
Schlickewei, C., Kleinertz, H., Thiesen, D. M., Mader, K., Priemel, M., Frosch, K., & Keller, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225805 · Cited by 128
“Sclerostin has been described as a direct inhibitor of LPR5, since sclerostin inactivation leads to the same bone phenotype as activating mutations of LRP5 with enhanced bone growth known as sclerosteosis [75,76].”
BackgroundThe Genetics of Low-Density Lipoprotein Receptor-Related Protein 5 in Bone: A Story of Extremes
Balemans, W., & Hul, W. V. (2007) · Endocrinology · doi:10.1210/en.2006-1352 · Cited by 116
Suen, P. K., & Qin, L. (2015) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2015.08.004 · Cited by 123
“Sclerostin is a secreted glycoprotein that is mainly expressed in bone matrix and cartilage matrix and has been reported to suppress the mineralization of osteoblasts in cell culture environment [36,40].”
BackgroundTargeting Wnt Pathways in Disease
Zimmerman, Z. F., Moon, R. T., & Chien, A. J. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008086 · Cited by 116
“Deficiency of a related mammalian gene product, sclerostin (SOST), is associated with the inherited disorder sclerosteosis, which results in hyperactive osteoblasts (Brunkow et al. 2001).”
BackgroundCrosstalk Between MLO‐Y4 Osteocytes and C2C12 Muscle Cells Is Mediated by the Wnt/β‐Catenin Pathway
Huang, J., Romero‐Suarez, S., Lara, N., Mo, C., Kaja, S., Brotto, L., Dallas, S. L., Johnson, M. L., Jähn, K., Bonewald, L. F., et al. (2017) · JBMR Plus · doi:10.1002/jbm4.10015 · Cited by 107
“Sclerostin is one of the osteocyte-specific proteins, and is product of the SOST gene (9), which is expressed by mature osteocytes (10, 11).”
BackgroundMolecular mechanisms of inflammatory bone damage: emerging targets for therapy
Herman, S., Krönke, G., & Schett, G. A. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.04.001 · Cited by 122
Early Brain Vulnerability in Wolfram Syndrome
Hershey, T. G., Lugar, H. M., Shimony, J. S., Rutlin, J. R., Koller, J. M., Perantie, D. C., Paciorkowski, A. R., Eisenstein, S. A., & Permutt, M. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040604 · Cited by 120
Novel actions of sclerostin on bone
Holdsworth, G., Roberts, S. J., & Ke, H. Z. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0176 · Cited by 118
Genetics of osteoporosis: accelerating pace in gene identification and validation
Li, W., Hou, S.-X., Yu, B., Li, M., Férec, C., & Chen, J. (2009) · Human Genetics · doi:10.1007/s00439-009-0773-z · Cited by 118
“tal overgrowth (Balemans et al. 2001; Brunkow et al. 2001).”
BackgroundOsteoanabolic Agents for Osteoporosis
Haas, A. V., & LeBoff, M. S. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00118 · Cited by 103
“Romosozumab was developed after the 2001 finding that sclerosteosis, a rare genetic disorder with high bonemass, was associated with a loss-of-functionmutation in the SOST gene that encodes sclerostin [23].”
Jaiprakash, A., Prasadam, I., Feng, J. Q., Liu, Y., Crawford, R., & Xiao, Y. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4221 · Cited by 98
“SOST knockout mice have a progressive high bone mass phenotype (21, 22).”
BackgroundReppe, S., Noer, A., Grimholt, R. M., Halldórsson, B. V., Medina-Gomez, C., Gautvik, V. T., Olstad, O. K., Berg, J. P., Datta, H., Estrada, K., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2342 · Cited by 101
BMP signaling in development and diseases: A pharmacological perspective
Bandyopadhyay, A., Yadav, P. S., & Prashar, P. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.01.004 · Cited by 115
Neural induction and early patterning in vertebrates
Ozair, M. Z., Kintner, C. R., & Brivanlou, A. H. (2012) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.90 · Cited by 118
Mechanotransduction via the Piezo1-Akt pathway underlies Sost suppression in osteocytes
Sasaki, F., Hayashi, M., Mouri, Y., Nakamura, S., Adachi, T., & Nakashima, T. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.10.174 · Cited by 99
Schwaninger, R., Rentsch, C. A., Wetterwald, A., van der Horst, G., van Bezooijen, R. L., van der Pluijm, G., Löwik, C. W. G. M., Ackermann, K., Pyerin, W. G., Hamdy, F. C., et al. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.051276 · Cited by 107
“A similar mechanism is at the origin of sclerosteosis, the sole example for a human congenital disease characterized by a generalized excess of bone formation.(23) Several BMPs have been shown to be produced by CaP cell lines.”
BackgroundNoggin and Sclerostin Bone Morphogenetic Protein Antagonists Form a Mutually Inhibitory Complex
Winkler, D. G., Yu, C., Geoghegan, J. C., Ojala, E. W., Skonier, J. E., Shpektor, D., Sutherland, M. K., & Latham, J. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400521200 · Cited by 105
Self-citationLrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption
Xiong, L., Jung, J.-U., Wu, H., Xia, W.-F., Pan, J.-X., Shen, C., Mei, L., & Xiong, W.-C. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419714112 · Cited by 103
Niedźwiedzki, T., & Filipowska, J. (2015) · Journal of Molecular Endocrinology · doi:10.1530/jme-15-0067 · Cited by 113
“2001, 2005, Brunkow et al .”
Sclerostin deficiency in humans
van Lierop, A. H., Appelman‐Dijkstra, N. M., & Papapoulos, S. E. (2016) · Bone · doi:10.1016/j.bone.2016.10.010 · Cited by 108
Role of CCN, a vertebrate specific gene family, in development
Katsube, K., Sakamoto, K., Tamamura, Y., & Yamaguchi, A. (2009) · Development, Growth & Differentiation · doi:10.1111/j.1440-169x.2009.01077.x · Cited by 103
Agonists and Antagonists of TGF-β Family Ligands
Chang, C. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a021923 · Cited by 94
Romosozumab for the treatment of osteoporosis
Bandeira, L., Lewiecki, E. M., & Bilezikian, J. P. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1280455 · Cited by 101
Targeting WNT signaling in the treatment of osteoporosis
Baron, R., & Gori, F. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.04.011 · Cited by 101
Stolina, M., Dwyer, D., Niu, Q., Villasenor, K. S., Kurimoto, P., Grisanti, M. S., Han, C.-Y. E., Liu, M., Li, X., Ominsky, M. S., et al. (2014) · Bone · doi:10.1016/j.bone.2014.07.031 · Cited by 105
“Sclerostin (Scl) is an endogenous inhibitor of osteoblasts that reduces bone formation and accrual of bonemass [1–3].”
BackgroundHoldsworth, G., Slocombe, P., Doyle, C., Sweeney, B., Veverka, V., Le Riche, K., Franklin, R. J., Compson, J., Brookings, D., Turner, J., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.350108 · Cited by 97
Wergedal, J. E., Veskovic, K., Hellan, M., Nyght, C., Balemans, W., Libanati, C., Vanhoenacker, F. M., Tan, J., Baylink, D. J., & Van Hul, W. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030201 · Cited by 98
“M IN THE region of the SOST gene on chromosome 17 have been identified with two similar diseases, sclerosteosis (1, 2) and Van Buchem disease or hyperostosis corticalis generalisata (3, 4).”
BackgroundEddleston, A., Marenzana, M., Moore, A. R., Stephens, P., Muzylak, M., Marshall, D., & Robinson, M. K. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090403 · Cited by 98
Sclerostin: from bench to bedside
Tanaka, S., & Matsumoto, T. (2020) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-020-01176-0 · Cited by 103
Singh, S., Dutta, S., Khasbage, S. U., Kumar, T., Sachin, J., Sharma, J., & Varthya, S. B. (2021) · Osteoporosis International · doi:10.1007/s00198-021-06095-y · Cited by 105
Balemans, W., Devogelaer, J., Cleiren, E., Piters, E., Caussin, E., & Hul, W. V. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070211 · Cited by 101
Chapter 13 Long‐Range Gene Control and Genetic Disease
Kleinjan, D. A., & Lettice, L. A. (2008) · Advances in genetics · doi:10.1016/s0065-2660(07)00013-2 · Cited by 109
“A gene encoding a negative regulator of bone formation, sclerostin (SOST), was found in this region (Balemans et al., 2001 ; Brunkow et al., 2001) and its expressionwas shown to be affected in both sclerosteosis andVanBuchemdisease.”
BackgroundDurosier, C., van Lierop, A., Ferrari, S., Chevalley, T., Papapoulos, S., & Rizzoli, R. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2113 · Cited by 94
Wnt signalling pathway: a new target for the treatment of osteoporosis
Rawadi, G., & Roman-Roman, S. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.5.1063 · Cited by 93
“Finally, Sost is a secreted protein characterised by a cysteine-knot motif and a significant similarity with the dan family of secreted glycoproteins (dan, cerberus/cer1, gremlin/drm, prdc, caronte and dante [84,85]).”
BackgroundMANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis
CANALIS, E. M. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0920 · Cited by 104
Hypoxia Signaling in the Skeleton: Implications for Bone Health
Yellowley, C. E., & Genetos, D. C. (2019) · Current Osteoporosis Reports · doi:10.1007/s11914-019-00500-6 · Cited by 95
Grabowski, P. (2009) · Endocrine Development · doi:10.1159/000223687 · Cited by 88
Kim, S. J., Biegański, T., Sohn, Y. B., Kozlowski, K. S., Semënov, M. V., Okamoto, N., Kim, C. H., Ko, A., Ahn, G., Choi, Y., et al. (2011) · Human Genetics · doi:10.1007/s00439-011-0947-3 · Cited by 94
“Sclerosteosis is an autosomal recessive disorder resulted from a null mutation of SOST, and a heterozygote carrier of the SOST null mutation is asymptomatic except for incidental reports of mildly increased bone mineral density (Balemans et al. 2001; Brunkow et al. 2001; Kim et al. 2008; Uitterlinden et al. 2004).”
BackgroundCis-ruption mechanisms: disruption of cis-regulatory control as a cause of human genetic disease
Kleinjan, D.-J., & Coutinho, P. (2009) · Briefings in Functional Genomics and Proteomics · doi:10.1093/bfgp/elp022 · Cited by 84
“malformation sclerosteosis (OMIM 269500) [9, 10].”
Genetic determinants of osteoporosis
Ralston, S. H. (2005) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000166385.62851.92 · Cited by 100
Editorial: Sclerostin and Wnt Signaling—The Pathway to Bone Strength
Ott, S. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2370 · Cited by 99
“Recently patients with sclerosteosis (15) and some patients with hyperostosis resembling Van Buchem’s disease (16, 17) were found to have homozygous mutations in the SOST gene.”
BackgroundRalston, S. H. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05317.x · Cited by 89
Clinical utility of serum sclerostin measurements
Clarke, B. L., & Drake, M. T. (2013) · BoneKEy Reports · doi:10.1038/bonekey.2013.95 · Cited by 89
“Among these secreted Wnt pathway antagonists is sclerostin, identified only a decade ago as a 213 amino-acid glycoprotein whose loss of function results in the autosomal recessive bone dysplasia sclerosteosis.(2,3) Sclerostin is secreted by osteocytes, and humans with inactivating sclerostin mutations have significant…”
BackgroundTeriparatide Treatment in Adult Patients with Osteogenesis Imperfecta Type I
Gatti, D., Rossini, M., Viapiana, O., Povino, M. R., Liuzza, S., Fracassi, E., Idolazzi, L., & Adami, S. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9770-2 · Cited by 92
Nakamura, Y., Weidinger, G., Liang, J. O., Aquilina-Beck, A., Tamai, K., Moon, R. T., & Warman, M. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32001 · Cited by 90
Mutations in DVL1 Cause an Osteosclerotic Form of Robinow Syndrome
Bunn, K. J., Daniel, P., Rösken, H. S., O’Neill, A. C., Cameron‐Christie, S., Morgan, T., Brunner, H. G., Lai, A., Kunst, H. P. M., Markie, D., et al. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.02.010 · Cited by 99
“A high-bone-mass phenotype (MIM 144750) is caused by gain-of-function mutations in LRP5 (MIM 603506),(6,7) whereas a reduction in expression or activity of the extracellular soluble Wnt antagonist SOST (MIM 605740) leads to van Buchem disease (MIM 239100)(8) and sclerosteosis type 1 (MIM 269500).(9) That”
BackgroundSclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis
Chen, X., Baum, W., Dwyer, D., Stock, M., Schwabe, K., Ke, H.-Z., Stolina, M., Schett, G. A., & Bözec, A. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203345 · Cited by 90
The genetics of bone mass and susceptibility to bone diseases
Karasik, D., Rivadeneira, F., & Johnson, M. L. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.48 · Cited by 94
Osterix and RUNX2 are Transcriptional Regulators of Sclerostin in Human Bone
Pérez-Campo, F. M., Santurtún, A., García‐Ibarbia, C., Pascual, M. A., Valero, C., Garcés, C. M., Sañudo, C., Zarrabeitia, M. T., & Riancho, J. A. (2016) · Calcified Tissue International · doi:10.1007/s00223-016-0144-4 · Cited by 93
Somatic activating mutations in MAP2K1 cause melorheostosis
Kang, H., Jha, S., Deng, Z., Fratzl‐Zelman, N., Cabral, W. A., Ivovic, A., Meylan, F., Hanson, E. P., Lange, E., Katz, J. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03720-z · Cited by 90
Roudier, M., Li, X., Niu, Q., Pacheco, E., Pretorius, J. K., Graham, K., Yoon, B. P., Gong, J., Warmington, K., Ke, H. Z., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37802 · Cited by 85
Romosozumab in osteoporosis: yesterday, today and tomorrow
Wu, D., Li, L., Wen, Z., & Wang, G. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04563-z · Cited by 95
“Loss of SOST gene function, which encodes sclerostin, was first reported in May 2001 [29].”
BackgroundLi, X., Ominsky, M. S., Warmington, K. S., Niu, Q., Asuncion, F., Barrero, M., Dwyer, D., Grisanti, M. S., Stolina, M., Kostenuik, P. J., et al. (2011) · Endocrinology · doi:10.1210/en.2011-0252 · Cited by 91
“The changes in serum biomarkers induced by Scl-Ab differ from those reported for human parathyroid hormone (PTH) (1-34).”
Backgroundde Vernejoul, M. C. (2008) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2007.12.011 · Cited by 88
Absence of sclerostin adversely affects B-cell survival
Cain, C. J., Rueda, R., McLelland, B., Collette, N. M., Loots, G. G., & Manilay, J. O. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1608 · Cited by 87
“Van Buchem’s disease in humans has been traced to a 52-kb deletion in the Sost regulatory region, which results in deforming increases in bone mass.((29)) Despite the clear role of SOST in the regulation of Wnt signaling, osteoblast activity, and the size of the BM cavity, the function of SOST in the regulation of bon…”
BackgroundMef2c deletion in osteocytes results in increased bone mass
Kramer, I., Baertschi, S., Halleux, C., Keller, H., & Kneissel, M. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1492 · Cited by 85
Uremic toxicity and sclerostin in chronic kidney disease patients
Desjardins, L., Liabeuf, S., de Oliveira, R. C., Louvet, L., Kamel, S., Lemke, H., Vanholder, R. C., Choukroun, G. J., & Massy, Z. A. (2014) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2014.04.002 · Cited by 91
Targeting the LRP5 Pathway Improves Bone Properties in a Mouse Model of Osteogenesis Imperfecta
Jacobsen, C. M., Barber, L. A., Ayturk, U. M., Roberts, H. J., Deal, L. E., Schwartz, M. A., Weis, M., Eyre, D., Zurakowski, D., Robling, A. G., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2198 · Cited by 83
“4 One strategy for increasing LRP5 signaling derives from the identification of mutations that compromise the expression or function of the LRP5 inhibitor SOST/sclerostin in individuals with van Buchem Disease or Sclerosteosis, respectively (17-20).”
Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts
Sutherland, M. K., Geoghegan, J. C., Yu, C., Winkler, D. G., & Latham, J. A. (2004) · Bone · doi:10.1016/j.bone.2004.04.019 · Cited by 93
New insights on the roles of BMP signaling in bone—A review of recent mouse genetic studies
Kamiya, N., & Mishina, Y. M. (2011) · BioFactors · doi:10.1002/biof.139 · Cited by 92
“In humans, loss-of-function and hypomorphic mutations in SOST cause sclerosteosis [76,77] and Van Buchem disease [78,79], respectively, with a HBM phenotype.”
The future of osteoporosis treatment – a research update
Lippuner, K. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13624 · Cited by 93
Fijalkowski, I., Geets, E., Steenackers, E., Van Hoof, V., Ramos, F. J., Mortier, G., Fortuna, A. M., Van Hul, W., & Boudin, E. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2782 · Cited by 82
Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models
Sebastian, A., & Loots, G. G. (2017) · Metabolism · doi:10.1016/j.metabol.2017.10.005 · Cited by 86
Fujita, K., Roforth, M. M., Demaray, S., McGregor, U., Kirmani, S., McCready, L. K., Peterson, J. M., Drake, M. T., Monroe, D. G., & Khosla, S. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3249 · Cited by 83
Bassett, J. H. D., Gogakos, A., White, J. K., Evans, H., Jacques, R. M., van der Spek, A. H., Sanger Mouse Genetics Project, Ramirez-Solis, R., Ryder, E., Sunter, D., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002858 · Cited by 82
Dixon, M. E., Armstrong, P. F., Stevens, D. B., & Bamshad, M. (2001) · Genetics in Medicine · doi:10.1097/00125817-200109000-00004 · Cited by 82
Matrix Mineralization as a Trigger for Osteocyte Maturation
Irie, K., Ejiri, S., Sakakura, Y., Shibui, T., & Yajima, T. (2008) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.2008.950527 · Cited by 81
“Loss of sclerostin in humans causes sclerosteosis and Van Buchem disease, both of which are characterized by a progressively sclerosing bone dysplasia with increased bone formation (Balemans et al. 2001; Brunkow et al. 2001).”
BackgroundTranscriptional control of Sost in bone
Sebastian, A., & Loots, G. G. (2017) · Bone · doi:10.1016/j.bone.2016.10.009 · Cited by 80
Sclerostin inhibits Wnt signaling through tandem interaction with two LRP6 ectodomains
Kim, J., Han, W., Park, T., Kim, E., Bang, I., Lee, H. S., Jeong, Y., Roh, K., Kim, J., Kim, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19155-4 · Cited by 88
Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases
Fabre, S., Funck‐Brentano, T., & Cohen-Solal, M. E. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113439 · Cited by 83
Sclerostin levels during growth in children
Kirmani, S., Amin, S., McCready, L. K., Atkinson, E. J., Melton, L. J., Müller, R., & Khosla, S. (2012) · Osteoporosis International · doi:10.1007/s00198-011-1669-z · Cited by 79
“Loss of function mutations in the sost gene or in its regulatory elements causes two rare human genetic disorders, sclerosteosis [7, 8] and van Buchem disease [9, 10] that result in high bone mass.”
BackgroundA generalized skeletal hyperostosis in two siblings caused by a novel mutation in the gene
Balemans, W., Cleiren, E., SIEBERS, U., Horst, J., & Hul, W. V. (2005) · Bone · doi:10.1016/j.bone.2005.02.019 · Cited by 81
“Although nonsense mutations in SOST (Gln24X, Trp124X, and Arg126X) seem to result in the sclerosteosis phenotype [16,17] and a regulatory mutation leads to van Buchem disease [21,22], no genotype–phenotype correlation could be observed for the splice site mutations.”
BackgroundInfluentialThe DAN family: Modulators of TGF‐β signaling and beyond
Nolan, K., & Thompson, T. B. (2014) · Protein Science · doi:10.1002/pro.2485 · Cited by 77
“the bone disorder sclerosteosis, with the disease being initially associated with a BMP inhibitory phenotype.(21) However, this phenotype has been reclassified, as SOST also shares the ability to antagonize Wnt signaling through a direct interaction with LRP5/LRP6.”
BackgroundTGF‐β signaling in human skeletal and patterning disorders
Serra, R. A., & Chang, C. (2003) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.10023 · Cited by 88
Genetics of osteoporosis: Symposium on ‘Genetic polymorphisms and disease risk’
Ralston, S. H. (2007) · Proceedings of the Nutrition Society · doi:10.1017/s002966510700540x · Cited by 79
“Mutations affecting the SOST gene, which encodes sclerostin, are the cause of the sclerosing bone dysplasias Van Buchem disease and sclerosteosis (Balemans et al. 2001, 2002b; Brunkow et al. 2001).”
Romosozumab: a Review of Efficacy, Safety, and Cardiovascular Risk
Fixen, C. W., & Tunoa, J. (2021) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00652-w · Cited by 80
β‐Catenin—A supporting role in the skeleton
Case, N. D., & Rubin, J. E. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22574 · Cited by 92
“Investigation of other mutations causing altered bone mass resulted in discovery of sclerostin [Brunkow et al., 2001], dickkopf-1 [Tian et al.”
BackgroundNMR structure of the Wnt modulator protein Sclerostin
Weidauer, S. E., Schmieder, P., Beerbaum, M., Schmitz, W., Oschkinat, H., & Mueller, T. D. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.01.062 · Cited by 89
“Whereas in Sclerosteosis missense mutations in the coding region were identified, a deletion in an enhancer region downstream of the SOST gene is causative for the van Buchem disease [3, 4 ].”
BackgroundOsteoporosis Treatment with Anti-Sclerostin Antibodies—Mechanisms of Action and Clinical Application
Rauner, M., Taipaleenmäki, H., Tsourdi, E. A., & Winter, E. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040787 · Cited by 83
Sclerostin antibody treatment improves fracture outcomes in a Type I diabetic mouse model
Yee, C. S., Xie, L., Hatsell, S. J., Hum, N. R., Murugesh, D. K., Economides, A. N., Loots, G. G., & Collette, N. M. (2015) · Bone · doi:10.1016/j.bone.2015.04.048 · Cited by 82
“In humans, lack of sclerostin causes sclerosteosis, a generalized skeletal hyperostosis disorder that results from elevated WNT signaling/osteoblast activity(30,31), while non-coding deletions of gene regulatory regions that control SOST expression result in similar bone overgrowth(28,32).”
BackgroundBone-to-Brain: A Round Trip in the Adaptation to Mechanical Stimuli
Gerosa, L., & Lombardi, G. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.623893 · Cited by 76
Prostaglandin E2 Signals Through PTGER2 to Regulate Sclerostin Expression
Genetos, D. C., Yellowley, C. E., & Loots, G. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017772 · Cited by 83
Hormonal and systemic regulation of sclerostin
Drake, M. T., & Khosla, S. (2017) · Bone · doi:10.1016/j.bone.2016.12.004 · Cited by 77
“humans and subsequently confirmed in murine models, inactivating mutations in SOST, the gene which encodes the sclerostin protein, are associated with significant increases in rates of bone formation and bone mass [1, 2].”
BackgroundChang, M.-K., Krämer, I., Keller, H., Gooi, J. H., Collett, C., Jenkins, D., Ettenberg, S. A., Cong, F., Halleux, C. M., & Kneissel, M. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2059 · Cited by 79
“Whether additional pathways such as the bone morphogenetic protein (BMP) signaling pathway((16,28,42,43)) or other targets interacting with sclerostin((44,45)) contribute to Sost deficiency–induced bone anabolism in the cancellous bone compartment remains to be addressed.”
BackgroundGatti, D., Viapiana, O., Adami, S., Idolazzi, L., Fracassi, E., & Rossini, M. (2011) · Bone · doi:10.1016/j.bone.2011.11.028 · Cited by 79
Nioi, P., Taylor, S., Hu, R., Pacheco, E., He, Y. D., Hamadeh, H., Paszty, C., Pyrah, I., Ominsky, M. S., & Boyce, R. W. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2482 · Cited by 74
Cbfa1/RUNX2 Directs Specific Expression of the Sclerosteosis Gene (SOST)
Sevetson, B., Taylor, S., & Pan, Y. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306249200 · Cited by 77
FoxOs, Wnts and oxidative stress-induced bone loss: new players in the periodontitis arena?
Galli, C., Passeri, G., & Macaluso, G. M. (2011) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.2011.01354.x · Cited by 84
A locus for asphyxiating thoracic dystrophy, ATD, maps to chromosome 15q13
Morgan, N. V., Bacchelli, C., Gissen, P., Morton, J., Ferrero, G. B., Silengo, M., Labrune, P., Casteels, I., Hall, C. M., Cox, P. M., et al. (2003) · Journal of Medical Genetics · doi:10.1136/jmg.40.6.431 · Cited by 76
Sclerostin Inhibition in the Management of Osteoporosis
Appelman‐Dijkstra, N. M., & Papapoulos, S. E. (2016) · Calcified Tissue International · doi:10.1007/s00223-016-0126-6 · Cited by 80
Effects of Age and Estrogen on Skeletal Gene Expression in Humans as Assessed by RNA Sequencing
Farr, J. N., Roforth, M. M., Fujita, K., Nicks, K. M., Cunningham, J. M., Atkinson, E. J., Therneau, T. M., McCready, L. K., Peterson, J. M., Drake, M. T., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138347 · Cited by 75
“Although originally discovered in rare human mutations affecting bone [39,40,41,42,43,44], mouse genetics has confirmed the importance of canonical Wnt signaling in the regulation of bone homeostasis [45].”
BackgroundHepatic Osteodystrophy—Molecular Mechanisms Proposed to Favor Its Development
Ehnert, S., Aspera-Werz, R. H., Ruoß, M., Dooley, S., Hengstler, J. G., Nadalin, S., Relja, B., Badke, A., & Nussler, A. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102555 · Cited by 72
Metadata
- Authors
- Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., Alisch, R. S., Gillett, L., Colbert, T., Tacconi, P., Galas, D., Hamersma, H., Beighton, P., & Mulligan, J. T.
- Affiliations
- University of Cape Town (ZA)
- University of Cagliari (IT)
- Corresponding author
- Brunkow, Mary E.
- ORCID
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2001-03
- Volume
- 68
- Issue
- 3
- Pages
- 577-589
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC1274471
- OpenAlex
- W2037750372
- Cited by
- 1,011
- References
- 50
- Citations by year
- 2026: 24 · 2025: 21 · 2024: 32 · 2023: 27 · 2022: 36 · 2021: 53 · 2020: 52 · 2019: 46 · 2018: 50 · 2017: 56 · 2016: 65 · 2015: 61 · 2014: 58 · 2013: 60 · 2012: 56
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4523 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Dermatological and Skeletal Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Keywords
- sclerosteosis, SOST gene, skeletal dysplasia, cystine knot proteins, bone homeostasis, skeletal overgrowth, nonsense mutation, splicing mutation, founder effect, Afrikaner population, bone formation regulation
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Bone Diseases, Chromosome Mapping, Chromosomes, Human, Pair 17, Consanguinity, Cystine, Female, Genetic Markers, Homozygote, Humans, Male, Molecular Sequence Data, Netherlands, Pedigree, Proteins, Recombination, Genetic, Sclerosis, Senegal, South Africa, Conserved Sequence, Alternative Splicing, Bone Morphogenetic Proteins, Mutation, Missense, Black People, White People, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.